Rehabkompassen®数字结构化随访工具促进卒中后患者定制化康复的随机对照多中心实用性试验研究方案
本研究为在瑞典开展的多中心、平行、开放标签、两臂实用性随机对照试验,计划纳入1106例成人卒中患者,按1:1随机分为对照组(n=553)和干预组(n=553)。主要结局为12个月随访时患者的独立性和社会参与,次要结局包括用户满意度、采用障碍与促进因素、其他卒中影响、健康相关生活质量及增量成本每质量调整生命年(QALY)的成本效果。
要点
- 计划纳入1106例成人卒中患者,干预组与对照组各553例,在3个月和12个月进行随访。
- 3个月随访时干预组使用Rehabkompassen®工具,对照组进行常规门诊访视;12个月随访时所有参与者均接受干预。
- 主要结局为12个月随访时的独立性和社会参与,次要结局包括满意度、障碍与促进因素、生活质量及成本效果。
核心结论
- 本试验结果将为Rehabkompassen®数字随访工具在卒中后急性期后连续照护中的作用提供临床实践和卫生政策依据。
研究设计与样本
- 在瑞典开展的多中心、平行、开放标签、两臂实用性随机对照试验,分配比例为1:1。
- 计划纳入1106例成人卒中患者,在卒中发病后3个月和12个月于常规照护场所进行随访。
- 3个月随访时,对照组(n=553)接受常规门诊访视,干预组(n=553)接受常规门诊访视加Rehabkompassen®工具。
- 12个月随访时所有参与者均接受干预。
主要发现
- 主要结局为12个月随访时患者的独立性和社会参与。
- 次要结局包括终端用户(患者和医疗从业人员)满意度、采用该工具的障碍与促进因素、其他卒中影响、健康相关生活质量,以及以增量成本每质量调整生命年(QALY)计算的成本效果。
- 访视后收集终端用户(患者和医疗从业人员)的反馈。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stroke is a leading cause of disability among adults worldwide. A timely structured follow-up tool to identify patients' rehabilitation needs and develop patient-tailored rehabilitation regimens to decrease disability is largely lacking in current stroke care. The overall purpose of this study is to evaluate the effectiveness of a novel digital follow-up tool, Rehabkompassen®, among persons discharged from acute care settings after a stroke. METHODS: This multicentre, parallel, open-label, two-arm pragmatic randomized controlled trial with an allocation ratio of 1:1 will be conducted in Sweden. A total of 1106 adult stroke patients will have follow-up visits in usual care settings at 3 and 12 months after stroke onset. At the 3-month follow-up, participants will have a usual outpatient visit without (control group, n = 553) or with (intervention group, n = 553) the Rehabkompassen® tool. All participants will receive the intervention at the 12-month follow-up visit. Feedback from the end-users (patient and health care practitioners) will be collected after the visits. The primary outcomes will be the patients' independence and social participation at the 12-month visits. Secondary outcomes will include end-users' satisfaction, barriers and facilitators for adopting the instrument, other stroke impacts, health-related quality of life and the cost-effectiveness of the instrument, calculated by incremental cost per quality-adjusted life year (QALY). DISCUSSION: The outcomes of this trial will inform clinical practice and health care policy on the role of the Rehabkompassen® digital follow-up tool in the post-acute continuum of care after stroke. TRIAL REGISTRATION: ClinicalTrials.gov NCT04915027. Registered on 4 June 2021. ISRCTN registry ISRCTN63166587. Registered on 21 August 2023.
引用
- Hu X, Liv P, Lundström E, et al. Study protocol for a randomized, controlled, multicentre, pragmatic trial with Rehabkompassen®-a digital structured follow-up tool for facilitating patient-tailored rehabilitation in persons after stroke. Trials. 2023. PMID: 37803460. doi:10.1186/s13063-023-07673-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。